Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $721,840.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Down 3.5 %

Shares of United Therapeutics stock opened at $386.27 on Friday. The company has a market capitalization of $17.25 billion, a PE ratio of 16.96, a PEG ratio of 1.17 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock’s fifty day simple moving average is $362.57 and its 200 day simple moving average is $326.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.38 EPS. Analysts predict that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of several research reports. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. HC Wainwright upped their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. LSV Asset Management increased its holdings in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Swedbank AB bought a new position in United Therapeutics during the 1st quarter worth about $97,316,000. FMR LLC increased its holdings in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.